Coherus BioSciences Q2 Adj EPS $(0.38) Beats $(0.52) Estimate, Sales $58.72M Beat $50.83M Estimate
Portfolio Pulse from bharat@benzinga.com
Coherus BioSciences reported Q2 adjusted EPS of $(0.38), beating the estimate of $(0.52) by 26.92%. The company also reported sales of $58.72M, surpassing the estimate of $50.83M by 15.51%. However, this represents a 2.39% decrease in sales compared to the same period last year.
August 04, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Coherus BioSciences reported better than expected Q2 results, which could positively impact the stock in the short term. However, the decrease in sales YoY might temper this positive impact.
Coherus BioSciences reported better than expected Q2 results, which is generally a positive signal for the stock. However, the decrease in sales compared to the same period last year might be a concern for investors, potentially tempering the positive impact of the earnings beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100